SYT Antibody (C-3): sc-390266

SYT Antibody (C-3) is a mouse monoclonal IgG2b antibody that detects SYT in mouse, rat, and human samples through applications such as western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), and enzyme-linked immunosorbent assay (ELISA). SYT, or synovial translocation protein, plays a crucial role as a transcriptional coactivator, facilitating the expression of genes involved in cell growth and differentiation, which is particularly important in the context of synovial sarcoma, a type of cancer that arises in soft tissues. Anti-SYT antibody (C-3) recognizes a protein featuring a conserved amino terminal SNH domain and a carboxy terminal QPGY domain, the latter of which acts as a transcriptional activating sequence. Notably, SYT is involved in a specific chromosomal translocation (t(x;18)) that leads to the fusion of its amino terminus with the carboxy terminus of SSX proteins, resulting in the formation of SYT-SSX chimeras that function as potent transcriptional activators. These chimeras are predominantly found in synovial sarcomas, which account for up to 10% of soft tissue sarcomas and can be classified into biphasic and monophasic subtypes based on the specific SSX fusion partner involved. SYT monoclonal antibody (C-3) detection of these critical protein interactions makes this reagent an invaluable tool for researchers studying the molecular mechanisms underlying synovial sarcoma and related pathologies.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

SYT Antibody (C-3) References:

1. Strong association of SYT-SSX fusion type and morphologic epithelial differentiation in synovial sarcoma.  |  Antonescu, CR., et al. 2000. Diagn Mol Pathol. 9: 1-8. PMID: 10718206
2. Splicing isoform of SYT-SSX fusion protein accelerates transcriptional activity and cell proliferation.  |  Morimoto, Y., et al. 2003. Cancer Lett. 199: 35-43. PMID: 12963121
3. Transcriptional co-activator activity of SYT is negatively regulated by BRM and Brg1.  |  Ishida, M., et al. 2004. Genes Cells. 9: 419-28. PMID: 15147271
4. The SYT-SSX fusion protein down-regulates the cell proliferation regulator COM1 in t(x;18) synovial sarcoma.  |  Ishida, M., et al. 2007. Mol Cell Biol. 27: 1348-55. PMID: 17101797
5. Synaptotagmin (Syt) IX is an essential determinant for protein sorting to secretory granules in mast cells.  |  Haberman, Y., et al. 2007. Blood. 109: 3385-92. PMID: 17164344
6. The proto-oncoprotein SYT (SS18) controls ATP release and regulates cyst formation by polarized MDCK cells.  |  Chittezhath, M., et al. 2008. Exp Cell Res. 314: 3551-62. PMID: 18835266
7. The synovial sarcoma-associated SYT-SSX2 oncogene antagonizes the polycomb complex protein Bmi1.  |  Barco, R., et al. 2009. PLoS One. 4: e5060. PMID: 19337376
8. Prognostic implication of SYT-SSX fusion type and clinicopathological parameters for tumor-related death, recurrence, and metastasis in synovial sarcoma.  |  Sun, Y., et al. 2009. Cancer Sci. 100: 1018-25. PMID: 19385976
9. Axonal and dendritic synaptotagmin isoforms revealed by a pHluorin-syt functional screen.  |  Dean, C., et al. 2012. Mol Biol Cell. 23: 1715-27. PMID: 22398727
10. Exploring Two Protocols of FISH Using Cytocell SYT-SSX Probe on Formalin Fixed Paraffin Embedded Tissue Sections.  |  Yajid, AI., et al. 2020. Asian Pac J Cancer Prev. 21: 1241-1245. PMID: 32458628

The preferred SYT antibody is SYT Antibody (D-3): sc-390615.